EGP-437 demonstrated better clinical performance than vehicle control, but did not meet its co-primary endpoints.

Kala Pharmaceuticals Inc. today announced positive top-line results from its confirmatory Phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery.

A thirty-something year old blind woman has her sight restored and sees her young baby for the first time; a 6-year-old boy regains his sight, and for the first time in his life, he sees the face of his parents.

Johnson & Johnson announced it will acquire Abbott Medical Optics for more than $4 billion. The deal is expected to close in the first quarter of 2017.

ATLANTA – Alcon (ACL), a division of Novartis (NVS), is investing $250 million into an expansion of its Atlanta-area facility that will add more than 300 jobs, the Atlanta Business […]